Catabasis Pharmaceuticals Priced, Nasdaq: CATB

Developing combined therapies for Duchenne muscular dystrophy and high cholesterol.

Industry: Health Care

Latest Trade: $2.25 0.00 (0.0%)

First Day Return: +8.3%

Return from IPO: -81.3%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on our proprietary Safely Metabolized And Rationally Targeted linker technology platform. Our SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple biological targets in one or more related disease pathways. We engineer bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of our proprietary SMART linkers. Our SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. Our initial focus is on treatments for rare diseases, such as Duchenne muscular dystrophy. We are also developing other product candidates for the treatment of serious lipid disorders. We target therapeutic areas and specific diseases with significant unmet medical need where we believe we will have a competitive advantage. We seek to develop therapies that modulate multiple targets in the disease pathway.
more less
IPO News for Catabasis Pharmaceuticals
more
IPO Data
IPO File Date 05/13/2015
Offer Price $12.00
Price Range $13.00 - $15.00
Offer Shares (mm) 5.0
Deal Size ($mm) $60
IPO Data
IPO Date 06/24/2015
Offer Price $12.00
Price Range $13.00 - $15.00
Offer Shares (mm) 5.0
Deal Size ($mm) $60
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2008
Employees 34
Website www.catabasis.com